Want to see FULC full AI Analyst Report?
Fulcrum Therapeutics (FULC) Stock Forecast & Price Target
520 Followers
FULC Analyst Ratings
Moderate Sell
0Buy1Hold1Sell
Based on 2 analysts giving stock ratings to Fulcrum Therapeutics in the past 3 months
FULC Stock 12 Month Forecast
Average Price Target
$3.00▼(-18.48% Downside)Based on 2 Wall Street analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a -18.48% change from the last price of $3.68.
Past 12 Months12 Month ForecastDec2025Sep2026
High$3.00
Average$3.00
Low$3.00
Highest Price TargetHighest$3.00Average Price Target$3.00Lowest Price TargetLowest$3.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Gregory Renza | Truist Financial | ― | hold | ― | Reiterated | 08/18/26 | ||
| Tazeen Ahmad | Bank of America Securities | $3 | sell | -18.48%Downside | Reiterated | 08/07/26 | ||
| Edward Tenthoff | Piper Sandler | $23→$3 | sell | -18.48%Downside | Downgraded | 06/02/26 | ||
| Joseph Schwartz | Leerink Partners | $24→$4 | hold | 8.70%Upside | Downgraded | 06/02/26 | ||
| Andrew Fein | H.C. Wainwright | $25→$3 | hold | -18.48%Downside | Downgraded | 06/02/26 | ||
| Anupam Rama | J.P. Morgan | ― | sell | ― | Downgraded | 06/02/26 | ||
| Luca Issi | RBC Capital | $10→$4 | hold | 8.70%Upside | Reiterated | 06/02/26 | ||
| Kristen Kluska | Cantor Fitzgerald | $24 | buy | 552.17%Upside | Reiterated | 03/19/26 | ||
| Matthew Biegler | Oppenheimer | $15 | buy | 307.61%Upside | Reiterated | 12/08/25 | ||
 Unknown AnalystNot Ranked | Roth MKM | $15 | buy | 307.61%Upside | Reiterated | 12/08/25 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Gregory RenzaTruist Financial | HoldReiterated | 08/18/26 | ― | ||
| Tazeen AhmadBank of America Securities | SellReiterated$3 | 08/07/26 | -18.48%Downside | ||
| Edward TenthoffPiper Sandler | SellDowngraded$23→$3 | 06/02/26 | -18.48%Downside | ||
| Joseph SchwartzLeerink Partners | HoldDowngraded$24→$4 | 06/02/26 | 8.70%Upside | ||
| Andrew FeinH.C. Wainwright | HoldDowngraded$25→$3 | 06/02/26 | -18.48%Downside | ||
| Anupam RamaJ.P. Morgan | SellDowngraded | 06/02/26 | ― | ||
| Luca IssiRBC Capital | HoldReiterated$10→$4 | 06/02/26 | 8.70%Upside | ||
| Kristen KluskaCantor Fitzgerald | BuyReiterated$24 | 03/19/26 | 552.17%Upside | ||
| Matthew BieglerOppenheimer | BuyReiterated$15 | 12/08/25 | 307.61%Upside | ||
| Unknown AnalystRoth MKMNot Ranked | BuyReiterated$15 | 12/08/25 | 307.61%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Fulcrum Therapeutics
3 Months
Success Rate10/18 ratings generated profit
56%
Average Return
+4.92%
Copying Matthew Biegler's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +4.92% per trade.
1 Year
Success Rate8/12 ratings generated profit
67%
Average Return
+5.97%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.97% per trade.
2 Years
Success Rate8/12 ratings generated profit
67%
Average Return
+27.88%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +27.88% per trade.
FULC Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 1 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 7 | 8 | 3 | 2 |
| Sell | 4 | 4 | 4 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 15 | 12 | 12 | 4 | 3 |
In the current month, FULC has received 0 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. FULC average Analyst price target in the past 3 months is 3.00.
FULC Financial Forecast
Consensus$0.00
FULC Sales Forecast
Next quarter’s sales forecast for FULC is $0 with a range of ― to ―. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
FULC Stock Forecast FAQ
What is FULC’s average 12-month price target, according to analysts?
Based on analyst ratings, Fulcrum Therapeutics’s 12-month average price target is $3.00.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FULC a Buy, Sell or Hold?
Fulcrum Therapeutics has a consensus rating of Moderate Sell which is based on 0 buy ratings, 1 hold ratings and 1 sell ratings.
What is Fulcrum Therapeutics’s price target?
The average price target for Fulcrum Therapeutics is $3.00. This is based on 2 12-month price targets, issued in the past 3 months. The highest analyst price target is $3.00, the lowest forecast is $3.00. The average price target represents a 18.48% decrease from the current price of $3.68.
What do analysts say about Fulcrum Therapeutics?
Fulcrum Therapeutics’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of FULC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
